SI1456238T1 - Proizvodnja f(ab)2 fragmentov v sesalskih celicah - Google Patents

Proizvodnja f(ab)2 fragmentov v sesalskih celicah

Info

Publication number
SI1456238T1
SI1456238T1 SI200230701T SI200230701T SI1456238T1 SI 1456238 T1 SI1456238 T1 SI 1456238T1 SI 200230701 T SI200230701 T SI 200230701T SI 200230701 T SI200230701 T SI 200230701T SI 1456238 T1 SI1456238 T1 SI 1456238T1
Authority
SI
Slovenia
Prior art keywords
fragments
production
mammalian cells
antibody fragments
bivalent
Prior art date
Application number
SI200230701T
Other languages
English (en)
Inventor
Abraham Bout
David Halford Ashton Jones
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of SI1456238T1 publication Critical patent/SI1456238T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200230701T 2001-12-17 2002-12-17 Proizvodnja f(ab)2 fragmentov v sesalskih celicah SI1456238T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL0100917 2001-12-17
EP02789019A EP1456238B1 (en) 2001-12-17 2002-12-17 Production of f(ab')2 fragments in mammalian cells
PCT/NL2002/000841 WO2003051927A2 (en) 2001-12-17 2002-12-17 Production of f(ab')2 fragments in mammalian cells

Publications (1)

Publication Number Publication Date
SI1456238T1 true SI1456238T1 (sl) 2008-08-31

Family

ID=19760784

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230701T SI1456238T1 (sl) 2001-12-17 2002-12-17 Proizvodnja f(ab)2 fragmentov v sesalskih celicah

Country Status (11)

Country Link
US (2) US20050048038A1 (sl)
EP (1) EP1456238B1 (sl)
AT (1) ATE397019T1 (sl)
AU (1) AU2002353662B2 (sl)
CA (1) CA2470579C (sl)
DE (1) DE60226896D1 (sl)
DK (1) DK1456238T3 (sl)
ES (1) ES2307807T3 (sl)
NZ (1) NZ533332A (sl)
SI (1) SI1456238T1 (sl)
WO (1) WO2003051927A2 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
DK1456238T3 (da) 2001-12-17 2008-08-18 Crucell Holland Bv Produktion af F(ab')2-fragmenter i pattedyrceller
CN101328473B (zh) 2003-05-09 2012-05-02 克鲁塞尔荷兰公司 E1-永生化的细胞培养物及培养所述细胞以提高从中获取的产物产量的方法
EP3680252A4 (en) 2017-10-02 2021-04-28 Laboratorios Silanes, S.A. de C.V. HIGH PERFORMANCE PROCESS FOR PREPARATION OF POISON ANTIDOTS WITH F (AB ') - 2 ANTIBODY FRAGMENTS
WO2023205656A2 (en) * 2022-04-18 2023-10-26 John Paul Ii Medical Research Institute Immortalized cells for production of bioproducts, methods of producing bioproducts with an immortalized cell, and methods of making immortalized cells for production of bioproducts

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
EP0173552B1 (en) * 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993006217A1 (en) * 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
EP0833934B2 (en) * 1995-06-15 2012-08-15 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
ATE536417T1 (de) * 1999-04-15 2011-12-15 Crucell Holland Bv Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
EP1130099A1 (en) * 2000-02-25 2001-09-05 Crucell Holland B.V. Activated vitronectin as a marker of angiogenesis detected with phage antibodies
DK1456238T3 (da) 2001-12-17 2008-08-18 Crucell Holland Bv Produktion af F(ab')2-fragmenter i pattedyrceller

Also Published As

Publication number Publication date
WO2003051927A2 (en) 2003-06-26
NZ533332A (en) 2005-07-29
EP1456238A2 (en) 2004-09-15
US7537916B2 (en) 2009-05-26
WO2003051927A3 (en) 2003-11-20
EP1456238B1 (en) 2008-05-28
AU2002353662B2 (en) 2009-04-23
CA2470579A1 (en) 2003-06-26
AU2002353662A1 (en) 2003-06-30
DK1456238T3 (da) 2008-08-18
US20080166767A1 (en) 2008-07-10
CA2470579C (en) 2012-03-06
ES2307807T3 (es) 2008-12-01
DE60226896D1 (de) 2008-07-10
US20050048038A1 (en) 2005-03-03
ATE397019T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
IL162648A0 (en) Cellular compositions and methods of making and using them
SI1456238T1 (sl) Proizvodnja f(ab)2 fragmentov v sesalskih celicah
PT1379671E (pt) Métodos de cultura de circovírus
TR200001946T2 (tr) Aşı
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
IL148060A0 (en) Compositions and methods for improved cell culture
DK1220934T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner med anvendelse af apoptoseinhibitorer
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
FR15C0055I2 (fr) Feuillets de l'epithelium corneen humain reconstitues in vitro et methode de production de ces derniers
NO20061470L (no) Fremgangsmate for fremstilling av gamma-karboksylerte proteiner
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
MX9710479A (es) Extracto de iridaceas y composiciones que la contienen.
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
EP1362093A4 (en) QUICK PRODUCTION OF MONOCLONAL ANTIBODIES
EP0434713A4 (en) Hiv-1 envelope muteins lacking hypervariable domains
CA2374003A1 (en) Improved cellular uptake of bioactive agents
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
AU4017501A (en) Cell culture spinner flasks
HK1063334A1 (en) Compositions and methods useful for hcv infection
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
WO2002022573A3 (en) Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
AUPQ994600A0 (en) Manipulation of plant senescene
MY133881A (en) "calcilytic compounds"